undamentalytics Newsletter
Sign in

Hyperfine, Inc. revenue

Hyperfine, Inc.'s revenue was $13.6m in fiscal 2025, up 5.2% on the year before. Since fiscal 2020 ($294,000) it has grown at a compound 115.2% a year. Over the last twelve months it was $16.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01711131417
Growth on the year before—+408.8%+355.5%+61.9%+16.8%+5.2%—
Gross profit−0−115679
Gross margin—−78.0%13.3%43.1%45.7%49.8%51.4%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $11.4M 84.0% ▲ 9.1%
Services $2.2M 16.0% ▼ 11.3%

From Hyperfine, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Hyperfine, Inc. $16.5m 53.2% 19.1%
Sensus Healthcare, Inc. $17.5m -53.4% -16.5%
Spectral AI, Inc. $15.4m -44.1% -11.8%
Jin Medical International Ltd. $20.7m -12.0% —
Nephros Inc $20.7m 24.2% 19.3%
Vivos Therapeutics, Inc. $20.9m 45.2% 10.6%

Compare with peers

Head to head: HYPR vs SRTSHYPR vs MDAIHYPR vs ZJYL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Hyperfine, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Hyperfine, Inc.